title: Epidermal growth factor prolongs survival time of tumor-bearing mice.
abstract: We observed that human epidermal growth factor (hEGF) alone prolonged the survival time of mice bearing various murine syngeneic tumors as well as athymic nude mice bearing human xenografts. No changes in the subcutaneous solid tumor mass volume were observed. Prolongation of survival time by hEGF was observed in mice bearing murine epidermoid carcinoma (BSC) and human gastric carcinoma (KATO III), but not in murine epidermoid carcinoma (KLN205) or human epidermoid carcinoma (A431). Human tumor cells such as A431, KATO III, and murine tumor cells, KLN205, BSC had roughly 2 X 10(6), 3 X 10(4), 1.3 X 10(3) and 1 X 10(3) EGF receptors/cell, respectively. Although KLN205 and BSC tumor cells maintained nearly the same number of EGF receptors, the effects of hEGF were very different. Although A431 tumor cells had nearly 100 times more receptors than KATO III cells, the prolongation of survival time of mice bearing A431 by hEGF was no better than that of mice bearing KATO III. Accordingly, it appears that this prolongation of survival time by hEGF is independent of the number of EGF receptors on tumor cells. In addition, hEGF was shown to inhibit experimental pulmonary metastasis of murine BSC tumor, but was ineffective with murine KLN205 tumor. These results suggest that prolongation of survival time by hEGF may result from the inhibition of tumor cell metastasis and EGF may play a role in preventing the metastasis of certain malignant neoplasms unrelated to its effects through the EGF receptor on tumor cells.
authors.affiliation: Institute for Medical Research, Wakunaga Pharmaceutical Co., Ltd., Hiroshima.
authors.forename: H
authors.initials: H
authors.lastname: Amagase
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: M
authors.initials: M
authors.lastname: Okuhira
authors.forename: M
authors.initials: M
authors.lastname: Kakimoto
authors.forename: H
authors.initials: H
authors.lastname: Amano
authors.forename: K
authors.initials: K
authors.lastname: Hashimoto
authors.forename: T
authors.initials: T
authors.lastname: Fuwa
authors.forename: S
authors.initials: S
authors.lastname: Tsukagoshi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality*; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000401:mortality*; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality*; D013997:Time Factors
chemical_list: D004815:Epidermal Growth Factor